Bio-Rad Reports Mixed 2025 Results with Significant Impairments Offset by Non-Operating Gain and Share Repurchases
BIO sits 21% above its 52-week low of $211.43 on elevated volume (2.1× avg).
Summary
Bio-Rad Laboratories reported a net income of $759.9 million for 2025, a significant improvement from a prior year loss, primarily due to a large non-operating gain from its Sartorius investment, despite flat sales and $172.8 million in impairment charges on acquired R&D assets.
Key Events · Earnings and Guidance · BIO
-
Significant Impairment Charges on Acquired R&D Assets
The company recorded $172.8 million in impairment charges related to in-process research and development (IPR&D) assets. This includes an $81.7 million impairment for the 2021 Dropworks acquisition due to delayed technology and revised forecasts, and a $127.7 million impairment for the 2022 Curiosity Diagnostics acquisition due to development discontinuation. This follows the 8-K disclosure on February 12, 2026, providing full details and context.
-
Net Income Driven by Non-Operating Gain
Bio-Rad reported a net income of $759.9 million ($27.85 diluted EPS) for 2025, a substantial improvement from a $1.84 billion net loss in 2024. This was primarily attributable to a $900.4 million gain from the change in fair market value of its investment in Sartorius AG.
-
Flat Sales and Declining Gross Margins
Net sales for 2025 were $2.58 billion, a modest 0.7% increase, with currency-neutral sales remaining essentially flat. Consolidated gross margin decreased by 1.8 percentage points to 51.9%, impacted by inventory write-offs and higher material costs.
-
Ongoing Share Repurchase Program
The company repurchased $295.5 million of Class A common stock in 2025. As of December 31, 2025, $284.6 million remained available under the $1 billion share repurchase program.
Analysis · BIO · Industrial Applications And Services
Bio-Rad Laboratories' 2025 annual report reveals a complex financial picture. While the company reported a substantial net income turnaround, this was largely driven by a non-operating gain from its investment in Sartorius AG, rather than core operational strength. The significant impairment charges on acquired R&D assets highlight challenges in product development and M&A integration. Investors should note the flat organic revenue growth and declining gross margins, which indicate underlying operational pressures. The ongoing share repurchase program is a positive for shareholder returns, but the overall sentiment remains mixed due to the operational headwinds.
At the time of this filing, BIO was trading at $255.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.9B. The 52-week trading range was $211.43 to $343.12. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.